|Post IPO Valuation|
|Description||Genomic Disease Management|
|IDEV Technologies, 7/2013||$310M|
|Facet Biotech, 3/2010||$450M|
|Solvay Pharmaceuticals, 9/2009||$6.6B|
|Ibis Biosciences, 12/2008||$215M|
|Debt, 3/2011 ||$100k|
Abbott Molecular Inc., a genomic disease management company, engages in the development and marketing of clinical laboratory products, which provide information critical to the evaluation and management of cancer, prenatal disorders, and other genetic diseases. It currently markets seven U.S. Food and Drug Administration or foreign cleared or approved clinical products in addition to distributing over 300 Analyte Specific Reagent and research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 59 countries. The company was founded in 1991 and is based in Des Plaines, Illinois. As on 12/05/2001, Abbott Molecular Inc. operates as a subsidiary of Abbott Laboratories Inc.